Diltiazem inhibits the spontaneous platelet aggregation in essential hypertension

Area of Science:

• Cardiology
• Pharmacology
• Hematology

Background:

• Essential hypertension is a significant risk factor for cardiovascular complications.
• Platelet aggregation plays a crucial role in the development of atherosclerosis and thrombosis.
• Understanding the effects of antihypertensive drugs on platelet function is important for comprehensive patient management.

Purpose of the Study:

• To investigate the impact of diltiazem therapy on platelet aggregation in patients with essential hypertension.
• To determine if diltiazem exhibits antiplatelet effects beyond its blood pressure-lowering action.

Main Methods:

• Assessed plasma beta-thromboglobulin levels.
• Measured initial (spontaneous) and total platelet aggregation induced by adrenaline and ADP.
• Evaluated these parameters in 15 essential hypertension patients before and after one week of diltiazem treatment (3 x 60 mg/day).

Main Results:

• Diltiazem therapy significantly decreased spontaneous platelet aggregation.
• No significant changes were reported for total platelet aggregation induced by adrenaline or ADP.
• Plasma beta-thromboglobulin levels were also assessed.

Conclusions:

• Diltiazem possesses antiplatelet properties, specifically reducing spontaneous platelet aggregation.
• This antiaggregatory effect may contribute to inhibiting atherosclerotic and thrombotic complications in essential hypertension.
• Diltiazem offers a dual benefit in managing essential hypertension by lowering blood pressure and reducing platelet hyperreactivity.